Mereo BioPharma Group PLC (MREO) Quote

MREO 10Q due 4/3

MREO 10Q due 3/27

LMAO

Responding to this post???

Not sure why you keep posting to me on this stock I've never been in it..

Hey thanks

Fireside chat at 11:20am (est.)…stay tuned

Not sure why you keep posting to me on this stock I've never been in it..

Hey thanks

Watch and learn as we approach 5 bucks

MREO new 52 week high

WATCH AND LEARN

MREO...CAN'T HURT THIS STOCK!!!!

MREO..THE HOTTEST BIO OUT THERE

That’s a real big boy. Lmao.

Should drop to the 20 day @1.96. Run don’t walk out this piggy

I like it, but when it goes thru that, $5’s & $6’s by end of Q1 after some readouts!!( look at 5yr chart)

2.97 WEEKLY RESISTANCE BY EOM

Do we break $3 by e.o.m???

Fake grandchildren are so adorable

You don’t trade real stocks for some odd reason, lol…I know why fake granny, so you may fool all the stupid men on this site, but most men are pathetic and easy to lie to.

I'm not even trading this I'm not even sure why he's posting to me and like I said I could give him fat frogs ass what he says to me..

Lol

I’m gonna stay out of this ‘love’ affair and just say that technically, ‘fundamentally’ and the fact that we have Whales in this ticker, $5 is realistic in 2024!! GLTA ( especially U2, lol) :)

Why are you posting to me I don't give a shit..

LMAO clients

Go lie on another border to somebody else.

MY CLIENTS HOLD 5000 SHARES EACH AT 1.13 THATS HOW THE BIG BOYS PLAY

Oh I believe you so does all of ihub with your credible reputation..

Lolzzzzzz

IT WAS SO HARD TO KEEP QUIET...LOL

Lolzzzzzzzzz

WAITING FOR THIS DAY A LONG TIME....LMAO...LOOK BELOW...2.52...MASTER ALWAYS GIVES NUMBERS

LOSS....THINK U HAVE LOST YOUR MARBELS...LONG AND STRONG GRANNY!

This is how the big boys play???

Lolzzzz

Who cares moron a loss is a loss great call..

Lolzzzzzzzzz

Huh closed $2.08

Is this how the big boys play??

Lol

MREO...GETTING VERY CLOSE TO THE RUMBLE IN THE JUNGLE WITH THAT 2.52 TARGET UP A HEAD

REMEMBER THE BUY OUT NEWS 2 YEARS AGO...Make me think theres an offer on the table!

MREO...2.35 TRIGGER IN AND NOW 2.52 IS NEXT

MREO READY FOR 2.52

MREO...HERE WE GO!

MREO...BREAKING OUT

MREO...2.52 COMING UP!!

Sweet, and more readouts on other P2/3 in pipeline

MREO BACK IN PLAY ON THE WEEKLY BREAK OUT

wow, nice...shit don't own it

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD)

Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET

NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker presentation at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR).

As of the cut-off date and following at least 6 months of treatment with setrusumab, the annualized fracture rate across all 24 patients in the Phase 2 portion of the study was reduced by 67%. In the 2 years prior to treatment with setrusumab all patients experienced at least 1 fracture. The median annualized fracture rate of 0.72 in the 2 years prior to treatment was reduced to 0.00 (n=24, p=0.042) during the mean treatment duration period of 9 months. Following initiation of treatment with setrusumab, 20 patients experienced no radiographic-confirmed fractures, and 4 patients experienced 7 radiographic-confirmed fractures in 5 separate events. These fractures exclude fractures of the fingers, toes, skull, and face consistent with the Phase 3 study design.

“I have not yet encountered a patient with a fragility fracture while on setrusumab, and this may result from setrusumab’s effects on the skeleton, improving the rate of new bone formation and bone quality,” said Gary Gottesman, M.D., Professor of Pediatrics and Medicine, Washington University School of Medicine. “Some of the kids feel well enough they are participating in activities that they might normally avoid and have suffered some relatively minor fractures.”

The reduction in annualized fracture rates was associated with a clinically meaningful increase in BMD. At the 6-month timepoint, treatment with setrusumab resulted in a mean increase in lumbar spine BMD from baseline of 13% at 20 mg/kg (n=11) and 16% at 40 mg/kg (n=8), which represents the same substantial mean improvement in Z-score of +0.85 for both dose groups at 6 months compared to a combined mean baseline Z-score of –1.68. The small apparent difference in BMD change from baseline is likely related to differences in patients assigned to the two treated groups. There was no statistically significant difference in BMD percent change or Z-score change from baseline between the 20 and 40 mg/kg dosing cohorts.

“These data provide compelling evidence that improved bone mineral density, resulting from this unique mechanism of action, reduced the risk of fractures and that treatment with setrusumab could allow patients with OI to lead much more active lives with fewer fractures,” said Eric Crombez, M.D., chief medical officer at Ultragenyx. “I want to acknowledge the OI community and especially thank the people living with OI and their caregivers who have aided the setrusumab development program so that we may potentially offer the first approved treatment option for this severe and disabling disease.”

As of the data cut-off, there were no treatment-related serious adverse events observed in the study. Reported adverse events were generally consistent with those observed in the ASTEROID study with infusion-related events and headache determined to be the most common adverse events related to the study drug. There have been no reported hypersensitivity reactions related to setrusumab. There were no notable safety-related differences observed between dosing groups or age groups.

The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries.

U.S. residents can learn more by visiting ultraclinicaltrials.com.

Analyst Day and Webcast Information

Ultragenyx will host an Analyst Day at 8:30 a.m. ET on Monday, October 16, 2023 to discuss these data and to provide an update on the company’s development pipeline. A live video webcast of the program will be available at https://www.webcaster4.com/Webcast/Page/359/49192.
An archived version of the remarks will also be available through the Ultragenyx website.

The Setrusumab Phase 3 Program

The global, seamless Phase 2/3 Orbit study is evaluating the effect of setrusumab on clinical fracture rate in patients aged 5 to

MREO by by 1.60s. Hello 1.70s.

NEXT STOP 1.85

SHORTS WORKED THE TOP AND WENT SHORT 590 000..... WHILE COVERING OVER 400 000 SHARES...THE 1,7 MILLION VOLUME SHARES REPRESENT OVER 1 MILLION SHARES BOUGHT AND SOLD BY RETAIL.

MREO....NICE SHAKE TO GET RID OF THE NELLIES AS WE APPROACH LIFT OFF...GAPPING IN PRE!!!

HERE WE GO...1.70S HITTING

WHEN THE BAKER BROS INVEST IN A STOCK, YA BETTER HOP ON.On July 31, 2023, BAKER BROS. ADVISORS LP purchased 14,604,391 shares of Mereo BioPharma Group PLC at a price of $1.33 per share. This transaction had an impact of 0.11 on the firm's portfolio. Following this acquisition, BAKER BROS. ADVISORS LP now holds a total of 14,604,391 shares in Mereo BioPharma Group PLC, representing 2.20% of the company's total shares...

ohhhh, you know what down lo is. you are about that life. don't play coy.

keep watching...its about to fly!!!

ohhhh, you know what down lo is. you are about that life. don't play coy.

what kind of English is that, you said you went to college..lol...watch and learn how its done!!